HPC
ITRM

HM Payson & Co’s Iterum Therapeutics ITRM Stock Holding History

HM Payson & Co’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$3 – 1105
2025
Q2 		$3 Hold
3
– – ﹤0.01% 996
2025
Q1 		$4 Hold
3
– – ﹤0.01% 1036
2024
Q4 		$6 Hold
3
– – ﹤0.01% 1033
2024
Q3 		$4 Hold
3
– – ﹤0.01% 1117
2024
Q2 		$4 Hold
3
– – ﹤0.01% 994
2024
Q1 		$5 Hold
3
– – ﹤0.01% 960
2023
Q4 		$6 Hold
3
– – ﹤0.01% 962
2023
Q3 		$3 Hold
3
– – ﹤0.01% 1000
2023
Q2 		$4 Hold
3
– – ﹤0.01% 994
2023
Q1 		$3 Hold
3
– – ﹤0.01% 1022
2022
Q4 		$3 Hold
3
– – ﹤0.01% 932
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1038
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1087
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1097
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1122
2021
Q3 		$0 Hold
3
– – ﹤0.01% 1105
2021
Q2 		$0 Hold
3
– – ﹤0.01% 1127
2021
Q1 		$0 Buy
+3
New +$71 ﹤0.01% 1150

Other funds holding ITRM

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $317M AUM 17.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

HM Payson & Co's ITRM Position: Q3 2025 in Review

HM Payson & Co sold out of Iterum Therapeutics (ITRM) in Q3 2025, closing a stake of 3 shares — an estimated $3 sold.

HM Payson & Co first reported a position in ITRM in Q1 2021 and held it in 18 quarters. The position peaked at $6 in Q4 2024. 24 funds tracked by Wall St. Rank hold ITRM as of Q3 2025.

  • HM Payson & Co reported no remaining Iterum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HM Payson & Co sold 3 Iterum Therapeutics shares in Q3 2025, an estimated $3.
  • HM Payson & Co first reported a position in Iterum Therapeutics in Q1 2021 and held it in 18 quarters.
  • HM Payson & Co's Iterum Therapeutics position peaked at $6 in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2025.

Based on HM Payson & Co's 13F filing for Q3 2025, filed 17 Oct 2025.